Abstract
Sepsis is a common and important cause of mortality in our intensive care units (ICUs). Since the recognition that bacterial toxins were associated with infection, we have come a long way in our understanding of this condition and its pathophysiology. As research continues, we increasingly realize the complexity of the septic process, an appropriate and necessary body response to infection or insult, which can become excessive and detrimental if control is lost. The resultant uncontrolled immunological host response may lead, on a downward spiral, to tissue damage and multiple organ failure. Metaphorically, one could compare the septic process and its mediators to an army of soldiers, well regimented and organized, responding in a controlled manner to defend its territory against invasion. If some, or all, of these soldiers lose their normal disciplined control, fighting can become frenzied and unpredictable, endangering not only the invader, but also the territory that the army was defending.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Members of the American College of Chest Physicians/ Society of Critical Care Medicine Consensus Conference Meeting. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864–74.
Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med 1996; 22: 707–10.
Weinstein SL, June CH, DeFranco AL. Lipopolysaccharide-induced protein tyrosine phosphorylation in human macrophages is mediated by CD14. J Immunol 1993; 151: 3829–38.
Haziot A, Rong GW, Lin XY, Silver J, Goyert SM. Recombinant soluble CD14 prevents mortality in mice treated with endotoxin (lipopolysaccharide). J Immunol 1995; 154: 6529–32.
Suffredini AF, Fromm RE, Parker MM, Brenner M, Kovacs JA, Wesley RA, Parrillo JE. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 1989; 321: 280–7.
O’Dwyer ST, Michie HR, Ziegler TR, Revhaug A, Smith RJ, Wilmore DW. A single dose of endotoxin increases intestinal permeability in healthy humans. Arch Surg 1988; 123: 1459–64.
Fong Y, Marano MA, Moldawer LL, Wei H, Calvano SE, Kenney JS, Allison AC, Cerami A, Shires GT, Lowri SF. The acute splanchnic and peripheral tissue metabolic response to endotoxin in humans. J Clin Invest 1990; 85: 1896–904.
Van Deventer SJ, Buller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A. Experimental endotoxemia in humans: Analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 1990; 76: 2520–6.
De La Cadena RA, Suffredini AF, Kaufman N, Parrillo JE, Colman RW. Activation of the kallikrein-kinin system after endotoxin administration to normal volunteers. Clin Res 1990: 38: 346A.
Martich GD, Danner RL, Ceska M, Suffredini AF. Detection of interleukin 8 and tumor necrosis factor in normal humans after intravenous endotoxin: the effect of antiinflammatory agents. J Exp Med 1991; 173: 1021–4.
Winkelstein JA, Tomasz A. Activation of the alternative complement pathway by pneumococcal cell wall teichoic acid. J Immunol 1978; 120: 174–8.
Hummel DS, Beringer RW, Tomasz A, Winkelstein JA. The fixation of C3b to pneumococcal cell wall polymers as a result of activation of the alternative complement pathway. J Immmunol 1981; 1127: 1287–9.
Ikejima T, Okusawa S, Van der Meer JWM, Dinarello CA. Toxic shock syndrome is mediated by interleukin 1 and tumor necrosis factor. Rev Infect Dis 1989; 11 (suppl 1): S316–5317.
Thiemermann C, Kengatharan M, De Kimpse SJ. Role of nitric oxide in the pathogenesis of septic shock. In: Vincent JL (ed), Yearbook of Intensive Care and Emergency Medicine. Springer-Verlag, Berlin, Heidelberg, New York, 1996; 345–357.
Michie HR, Manogue KR, Spriggs DR, Revhaug A, O’Dwyer S, Dinarello CA, Cerami A, Wolff SM, Wilmore DW. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 1988; 318: 1481–1486.
Calandra T, Baumgartner JD, Grau DG, Wu MM, Lambert PH, Schellekens J, Verhoef J, Glauser MP. Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha, and interferon-gamma in the serum of patients with septic shock. J Infect Dis 1990; 161: 982–987.
Okusawa S, Gelfand JA, Ikejima T, Connolly IU, Dinarello CA. Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest 1988; 81: 1162–1172.
Vincent JL, Bakker J, Marécaux G, Schandene L, Kahn RJ, Dupont E. Administration of anti-TNF antibody improves left ventricular function in septic shock patients. Chest 1992; 101: 810–815.
Tracey KJ, Fong Y, Hesse D. Anticachectin/TNS alpha monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330: 662–664.
Silva AT, Bayston KF, Cohen J. Prophylactic and therapeutic effects of a monoclonal antibody to tumor necrosis fractor-a in experimental gram-negative shock. J Infect Dis 1990; 162: 421–427.
Marchant A, Devière J, Byl B, De Groote D, Vincent JL. Interleukin-10 production during septicemia. Lancet 1994; 344: 707–708.
Anderson BO, Bensard DD, Harken AH. The role of platelet activating factor and its antagonists in shock, sepsis and multiple organ failure. Surg Gynecol Obstet 1991; 172: 415–424.
Dhainaut JF, Tenaillon A, Letulzo Y, Schlemmer B, Solet JP, Wolff M, Holzapfel L, Zeni F, Dreyfuss D, Mira JP, Chrétien JM, Lavergne V, Guinot P, Sepsis Study Group. Efficacy of PAF antagonist (BN52021) in reducing mortality of patients with severe gram-negative sepsis. Circ Shock 1993; 1: 42.
Bernard GR, Reines HD, Halushka PV, Higgins SB, Metz CA, Swindell BB, Wright PE, Watts FL, Vrbanac JJ. Prostacyclin and thromboxane-A2 formation is increased in human sepsis syndrome—Effects of cyclooxygenase inhibition. Am Rev Respir Dis 1991; 144: 1095–1101.
Van der Poll T, Levi M, Buller HR, Van Deventer SJ, De Poer JP, Hack CE, ten Cate JW. Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med 1991; 174: 729–732.
Mulder MF, Lambalgen AA, Huisman E, Visser JJ, Van den Bos GC, Thijs LG. Protective role of NO in the regional hemodynamic changes during acute endotoxernia in rats. Am J Physiol 1994; 266: H1558–H1564.
Meyer J, Lentz CW, Stothert JC, Traber LD, Herndon DN, Traber DL. Effects of nitric oxide synthesis inhibition in hyperdynamic endotoxemia. Crit Care Med 1994; 22: 306–312.
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Vincent, JL. (1998). Pathophysiology of the sepsis syndrome. In: Critical Care Nephrology. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-5482-6_40
Download citation
DOI: https://doi.org/10.1007/978-94-011-5482-6_40
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-6306-7
Online ISBN: 978-94-011-5482-6
eBook Packages: Springer Book Archive